PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Tag: cancer
Encapsulated Papillary Carcinoma Membrane Characteristics
Encapsulated Papillary Carcinoma Membrane Characteristics Overview This study focused on encapsulated papillary carcinoma (EPC), a type of breast carcinoma characterized by a thick fibrous capsule-like structure surrounding the tumor, often interpreted as a thickened basement membrane (BM). The primary objective was to investigate the geometric properties of the EPC capsule and determine
Ibrutinib Treatment In Waldenström Macroglobulinemia
Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications Gastric or stomach cancer prevalence varies significantly around the world, with higher rates in Asia, Africa, South America, and Eastern Europe. However, in the United States, stomach cancer is a growing concern due to its increased occurrence in the elderly population and its
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Postoperative Delirium In The NICU: Hormonal Risk Factors
Postoperative Delirium In The NICU: Hormonal Risk Factors In neurosurgery, pituitary adenoma ranks as the second most common brain tumor. Recent advances in endoscope-assisted transsphenoidal surgery have revolutionized tumor resection, reducing complications. However, postoperative complications, particularly endocrine-related issues, remain critical in neurosurgical intensive care units (NICUs). Notably, postoperative delirium, intricately linked
Cancer Care: Gender Bias In Decision-Making
Cancer Care: Gender Bias In Decision-Making Overview In the realm of cancer care, the integration and execution of shared decision-making within clinical practice guidelines (CPGs) and consensus statements could potentially exhibit gender-based disparities. This study aimed to meticulously analyze recommendations pertaining to shared decision-making within CPGs and consensus statements, specifically focusing on
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits
Eosinophilic Dermatosis In Hematological Malignancy (EDHM): Case Study Reports
Eosinophilic Dermatosis In Malignancy (EDHM): Case Study Reports Overview Patients with hematological malignancies may develop various skin eruptions, and one such condition is eosinophilic dermatosis of hematological malignancy (EDHM), also known as an 'insect bite-like' reaction. While cutaneous reactions are not uncommon in hematological malignancies, EDHM is a relatively rare condition that
Uterine Leiomyosarcoma: A Meta-Analysis Of Systemic Therapy Effectiveness
Uterine Leiomyosarcoma: Systemic Therapy Effectiveness Overview Uterine leiomyosarcoma (uLMS) is an aggressive type of mesenchymal tumor linked to a bleak prognosis. The primary treatment for advanced uLMS is systemic chemotherapy, although the most effective regimen remains uncertain. To address this, we conducted an extensive analysis, including both meta-analysis and metaregression, aiming to
